Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines:: a report from the Groupe Francais d'Immunotherapie
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines:: a report from the Groupe Francais d'Immunotherapie
复制标题
DOI：
10.1093/annonc/mdf257
复制
发表时间：
2002-09-01
影响因子：
50.5
通讯作者：
Lasset, C
中科院分区：
文献类型：
--
作者：
Négrier, S;Escudier, B;Lasset, C
白细胞介素-2（IL-2）或/和干扰素（IFN）常规用于治疗患有转移性肾细胞癌的患者。然而.结果令人失望，大多数治疗失败。在6年多的时间里，法国免疫治疗集团在使用细胞因子方案的连续多中心试验中招募了782名患者。对这个大型前瞻性数据库进行单变量和多变量分析，以确定影响生存率的预后因素。
Interleukin-2 (IL-2) or/and interferon (IFN) are routinely used for treating patients with metastatic renal cell cancer. However. results have been disappointing, with a majority of treatment failure. Over 6 years, the Groupe Francais d'Immunotherapie enrolled 782 patients in successive multicenter trials using cytokine regimens. Univariate and multivartate analyses were performed on this large prospective database to identify prognostic factors for survival The presence of biological signs of inflammation, short time interval front renal tumor to metastases (